Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

(2017) Katharine A. Collins et al.   Scientific Reports

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice

(2016) Karin Lövgren Bengtsson et al.   VACCINE

Viral vector-based influenza vaccines

(2016) Rory D. de Vries et al.   Human Vaccines & Immunotherapeutics

Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01

(2016) Sophie Detienne et al.   Scientific Reports

Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid–season results

(2015) R G Pebody et al.   Eurosurveillance

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015

(2015) D M Skowronski et al.   Eurosurveillance

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans

(2015) Ka Yan Chung et al.   VACCINE

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

(2015) E. T. Overton et al.   Open Forum Infectious Diseases

Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge

(2015) Freek Cox et al.   PLoS One

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

(2014) Arwen Altenburg et al.   Viruses-Basel

Matrix-M™ adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen

(2013) Karin Lövgren Bengtsson et al.   Expert Review of Vaccines

Adjuvanted influenza vaccines

(2013) Orli Even-Or et al.   Expert Review of Vaccines

Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases

(2013) Chunfeng Qu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution

(2013) B. F. Koel et al.   SCIENCE

Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice

(2013) Sofia E. Magnusson et al.   VACCINE

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice

(2013) George M Warimwe et al.   Virology Journal

Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution

(2012) K. B. Westgeest et al.   JOURNAL OF GENERAL VIROLOGY

Lymph Node Macrophages

(2012) Elizabeth E. Gray et al.   Journal of Innate Immunity

Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen

(2012) Jenny M. Reimer et al.   PLoS One

Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model

(2011) Gabriel Pedersen et al.   Influenza and Other Respiratory Viruses

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

(2011) Rebecca J. Cox et al.   VACCINE

Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression

(2009) M. H. Lehmann et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations

(2009) Karl G. Nicholson et al.   VACCINE

Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice

(2009) Abdullah S. Madhun et al.   VACCINE

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants

(2008) Katarina Radošević et al.   VACCINE